ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
Alexion Pharmaceuticals Inc

Alexion Pharmaceuticals Inc (ALXN)

182.50
0.00
(0.00%)
종가: 27 11월 6:00AM
182.50
0.00
( 0.00% )
시간외 거래: -

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

가격
182.50
매수가
183.00
매도가
185.00
거래량
-
0.00 일간 변동폭 0.00
0.00 52주 범위 0.00
전일 종가
182.50
개장가
-
최근 거래 시간
마지막 거래 시간
-
평균 볼륨(3m)
-
재정 규모
-
VWAP
-

ALXN 최신 뉴스

알렉시온, 화이자 유전자 치료제를 10억 달러 인수 합의

ADVFN – 새로운 유전자 치료법에 베팅하는 아스트라제네카는 금요일 이 회사의 알렉시온(NASDAQ:ALXN) 사업부가 미국 제약회사 화이자(NYSE:PFE)의 초기 단계 희귀 질환 유전자 치료제 포트폴리오를 최대...

아스트라제네카, 항암제 수요로 2분기 결과 예상치 상회

ADVFN – 아스트라제네카는 블록버스터 항암제의 강력한 실적이 COVID-19 백신 판매 손실을 상쇄하는 데 도움이 되면서 2분기에 예상보다 나은 이익과 매출을 기록했다고 금요일 발표했다. 이 앵글로-스웨...

Moderna Set to Join S&P 500

Moderna Set to Join S&P 500 PR Newswire NEW YORK, July 15, 2021 NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the...

Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized My...

– Study met primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26 – – ULTOMIRIS demonstrated compelling efficacy as...

Honeywell International Inc. to Join the NASDAQ-100 Index Beginning July 21, 2021

NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Honeywell International Inc. (Nasdaq: HON), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX...

Caelum & Alexion Present Additional Phase 2 Data Reinforcing Safety & Tolerability of CAEL-101 in AL Amyloidosis at the Europ...

- Exploratory biomarker analyses suggest possible cardiac disease improvements and renal response - Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2...

 Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children & Adolescents with Paroxysmal Nocturnal Hemog...

 – With this approval, ULTOMIRIS is the first and only medicine approved in the U.S. to treat children and adolescents with PNH – – Approval based on interim results from Phase 3 study showing...

Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021

- Accepted abstracts include new Phase 2 safety and tolerability data for CAEL-101 in AL amyloidosis - - Phase 3 studies of CAEL-101 in AL amyloidosis are underway - Caelum Biosciences and...

Alexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress

– Long-term data evaluate the effectiveness of ULTOMIRIS® (ravulizumab-cwvz) in reducing the risk of thrombosis in PNH, the primary cause of organ damage and premature death in untreated patients...

Alexion Shareholders Approve Acquisition by AstraZeneca

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
IFBDInfobird Company Ltd
US$ 3.35
(84.07%)
3.04M
MTEMMolecular Templates Inc
US$ 0.4734
(27.95%)
1.55M
AMBAAmbarella Inc
US$ 83.31
(21.78%)
426.5k
EVTVEnvirotech Vehicles Inc
US$ 1.54
(14.07%)
389.74k
TRIBTrinity Biotech PLC
US$ 1.28
(12.28%)
300
PGHLPrimega Group Holdings Ltd
US$ 12.75
(-88.12%)
1.18M
BSFCBlue Star Foods Corporation
US$ 0.311
(-15.95%)
2.1M
IMGCIMG Inc
US$ 1.35
(-15.63%)
2.25M
ZENAZenaTech Inc
US$ 9.25
(-10.19%)
634.11k
KWEKWESST Micro Systems Inc
US$ 0.72
(-9.43%)
16.21k
ELABElevai Labs Inc
US$ 0.0121
(-3.20%)
10.09M
IGFiShares Global Infrastructure
US$ 55.25
(0.00%)
4.76M
IDAIT Stamp Inc
US$ 0.3958
(8.44%)
4.04M
NKLANikola Corporation
US$ 1.96
(0.51%)
3.06M
IFBDInfobird Company Ltd
US$ 3.35
(84.07%)
3.04M

ALXN Discussion

게시물 보기
whytestocks whytestocks 4 년 전
JUST IN: $ALXN 2 Top Pharma Stocks to Buy Right Now

Most of us don't choose when to be sick, what illness will befall us, or what medicine we will take to recover. Thankfully, the pharmaceutical industry -- which is responsible for developing life-saving drugs -- never sleeps. While this sector has not escaped the COVID-19-induced economic c...

In case you are interested ALXN - 2 Top Pharma Stocks to Buy Right Now
👍️0
whytestocks whytestocks 4 년 전
JUST IN: $ALXN Labor Day Special: 3 Deep-Discount Stocks to Buy Now

Every year since 1894, the first Monday in September has been a federally recognized holiday to "celebrate the social and economic achievements of American workers," according to the U.S. Department of Labor.  However, Labor Day has taken on a completely different feel in 2020. The coronav...

In case you are interested ALXN - Labor Day Special: 3 Deep-Discount Stocks to Buy Now
👍️0
Renee Renee 4 년 전
ALXN SEC Admin. Proceeding: Cease and Desist Order:

https://www.sec.gov/litigation/admin/2020/34-89214.pdf
👍️0
Inthe203 Inthe203 5 년 전
This Pharma is in due diligence with another one right now, so I heard. Rumor has it, Alexion is being bought.
👍️0
Inthe203 Inthe203 5 년 전
ALEXION BEING SOLD TO ANOTHER PHARMA!

👍️0
ADVFN_sidvicious ADVFN_sidvicious 5 년 전
1 billion in share buy back!!!! YES!
👍️0
ADVFN_sidvicious ADVFN_sidvicious 5 년 전
LetterPenny, now that’s what I am talking about brother!
👍️0
ADVFN_sidvicious ADVFN_sidvicious 5 년 전
LetterPenny... did you see they got approval?... hopefully that will offset the debt of the recent acquisition.
👍️0
ADVFN_sidvicious ADVFN_sidvicious 5 년 전
Absolutely agree a good buy at this market price
👍️0
Letterpenny Letterpenny 5 년 전
Alexion puts in stalking bid for Bertilimumab. The next big thing. Maybe they get a great deal.
👍️0
stocktrademan stocktrademan 7 년 전
ALXN buy 129.83



















normal chart




log chart



👍️0
Inthe203 Inthe203 7 년 전
** PENDING BUYOUT! LOAD UP FOLKS!!!!

RUMOR HAS IT that recent events of moving to Boston is due to a pending buyout! This is a strategic move to tighten the pursestrings and clean up the books!

MY SOURCES HAVE ALWAYS BEEN ACCURATE!

👍️0
Inthe203 Inthe203 7 년 전
ALEXION TRIMMING THE FAT

SEE? I wasn't lying!

They are laying off 50% of their workforce, getting rid of 60% of their compounds, consolidating building and moving to Boston, all to save shareholders money.

This will initially be a HUGE hit to the PPS. We should see a record $70.00 PPS.

However, it really should bounce back immediately up to the $180's in my opinion, as this will become a more leaner company with better profit margins.

👍️0
Pony up Pony up 7 년 전
Is the pipeline rich?
👍️0
raff raff 7 년 전
Apparently, Soliris drug sales are increasing. But..

https://alphastreet.com/bite/4dac307

But how long can this company run on this? Given, the company has also announced that it is reducing the R&D expense for the year.
👍️0
Inthe203 Inthe203 7 년 전
LAYOFFS ARE LOOMING!

Stocks will be affected - time is ticking! Dump while you can, folks!
👍️0
Inthe203 Inthe203 7 년 전
CASH IN WHILE IT'S ON A HIGH!

https://seekingalpha.com/news/3273272-alexion-sputtering-kanuma-launch-write-looming

In this seeking alpha article, it clearly indicates where this company is heading. CEO Ludwig Hantson, is notorious for going into Pharmas, trimming the fat and preparing it for a buyout. That executive team that he brought in? They're all a part of the buyout team he formed in the other companies he spearheaded.

As you can see here, he's trimming the fat and I suspect he's getting rid of Alexion's metabolical area which has proven to be disastrous to the company. The article mentions Kanuma being written off, but I suspect that Strensiq will be a part of the deal as well, as both drugs has performed poorly in sales. The didn't include Strensiq as not to alarm the shareholders, but clearly that drug's sales performance is poor as well.

This means Alexion will become a one-hit-wonder again which will result in another wave of massive layoffs which I can only imagine will come before August in my opinion.

I don't even think there's anything else in the company's pipeline that's worthy at this point, is there?

The question is, who's buying them out?





👍️0
Mdragonpkf Mdragonpkf 7 년 전
On the up n up!
👍️0
cashmoneykid77 cashmoneykid77 7 년 전
good ill buy more
👍️0
Inthe203 Inthe203 7 년 전
OH WAIT UNTIL NEXT WEEK FOLKS!

I SMELL $80 BUCKS A SHARE! COUNTDOWN BEGINS!
👍️0
Mdragonpkf Mdragonpkf 7 년 전
Up up and away hey, starting next week
👍️0
Inthe203 Inthe203 7 년 전
LOL!

Delusional.

You're all in for a rude awakening. Sit back and watch :)
👍️0
cashmoneykid77 cashmoneykid77 7 년 전
Honestly all that I care about is the fact that Martin Shkreli is in $ALXN balls deep. Hes started numerous pharmaceutical companies and created pharmaceuticals himself. Not many people know the space better than he does, and not gonna pretend like any of my own DD will have a spec of impact. He believes the company is worth 2 to 3 times its current price. See you guys at $200.00
👍️0
Dr_Thorfin Dr_Thorfin 7 년 전
I thought message boards were here to share information related to these stocks.
Guess at ALXN you guys take it too personal.
Its just a stock dude, is there a reason for your anger?
👍️0
Inthe203 Inthe203 7 년 전
Sure, whatever makes you sleep at night.

So sorry your stocks are under water that you have to pump a stock :(
👍️0
Dr_Thorfin Dr_Thorfin 7 년 전
LOL
most people online claiming to live in $4m homes live in their parents basement.
But okay, the bet is on
👍️0
Inthe203 Inthe203 7 년 전
I will mortgage my home and bet 4M in cash that it will NOT be approved (if at all) for 3 years.

You're delusional and don't know the first thing about it. Your field is investments. You may be seated.
👍️0
Dr_Thorfin Dr_Thorfin 7 년 전
Quote- "“I have never seen the clinical responses that I’ve observed in IgA nephropathy patients treated with OMS721,” stated Geoffrey Block, M.D., Director of Clinical Research at Denver Nephrology and Principal Investigator of the trial. “All of these patients had significant renal impairment when they entered the trial and each patient dramatically improved. The improvements in these patients continued to increase after the end of treatment and persisted following completion of the trial. As an active clinical investigator, given the strength of these data, I am working hard to move this promising drug through the clinical trial process.”--
👍️0
Inthe203 Inthe203 7 년 전
That's far fetched and will not happen.

This is 2 - 3 years out. That's wishful thinking and just a ploy for you to pump their stock.

Alexion is tanking on due to their own mistakes - their biggest was acquiring Synageva which is bleeding them dry.

The drug you mentioned, if approved will be the nail on the coffin - as their drug requires a 24 hour drip at a high price tag.

Alexion's PPS should hover around 55 - 60 at the most. More layoffs are on the way, you'll see.

Fish out of water have a better chance of surviving than ALXN!

👍️0
Dr_Thorfin Dr_Thorfin 7 년 전
FDA sugest them to file for BTD , due to the impressive data from phase 2
Could go real fast for OMER
👍️0
Inthe203 Inthe203 7 년 전
Don't spread lies.

They are at least 2-3 years away from being approved. Just entered Phase 3.

R&D takes 10 years.

http://www.omeros.com/images/pipeline-4-6-2017-large.png




👍️0
Dr_Thorfin Dr_Thorfin 7 년 전
They always say buy before leaving a sinking ship,
They know omeros has a better product , ready to be approved
👍️0
Dutchdaan Dutchdaan 8 년 전
newbs sellingggg. big $$ to be made here!
👍️0
Dutchdaan Dutchdaan 8 년 전
Where is Alexion Pharmaceuticals' stock going? Where will Alexion Pharmaceuticals' stock price be in 2017?

24 equities research analysts have issued 1 year target prices for Alexion Pharmaceuticals' stock. Their predictions range from $120.00 to $221.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $165.36 in the next twelve months.
👍️0
Dutchdaan Dutchdaan 8 년 전
Adam Feuerstein, martin and goldman say buy its a rare opportunity plus myself. you dont get better picks.
👍️0
Inthe203 Inthe203 8 년 전
With nothing good in their pipeline and their failed projection in sales, you've been sold a bill of goods!

I can't wait to check back with you in 6 months!

Have fun!
👍️0
Dutchdaan Dutchdaan 8 년 전
see you at $200 in 6 months BRO
👍️0
Inthe203 Inthe203 8 년 전
I know, peanut. Rare to buy into a failing company. Good for you! Congrats!
👍️0
Dutchdaan Dutchdaan 8 년 전
no i just started buying last week. and will add. it is a rare opportunity.
👍️0
Inthe203 Inthe203 8 년 전
Sure :)

Sorry you're under water.

👍️0
Dutchdaan Dutchdaan 8 년 전
$ALXN lol green close coming!! this is going back to 200$ THIS IS THE NEXT ABBV
👍️0
Inthe203 Inthe203 8 년 전
ASK THE CEO FOR A HEAD COUNT OF EMPLOYEES!

You may be surprised!

ASK THE CEO ABOUT SALES!!!

You may be surprised!

ASK THE CEO ABOUT STABILITY!!!

You may be surprised!


SELL YOUR SHARES WHILE THEY ARE STILL IN THE $90'S, FOLKS!
👍️0
Inthe203 Inthe203 8 년 전
Let's focus, peanut.

The only difference between Alexion and the Titanic is that the Titanic had a band as it was sinking.

You'll see when it hits $60 PPS. You'll be wishing you sold now.
👍️0
Dutchdaan Dutchdaan 8 년 전
Sure. and their batteries last for weeks right? way better then Teslas batteries and they are on the otc and nobody heared of them. it is some magical chinese investor making 10 times better batteries then tesla.. things like that dont happen irl. Technology is with with universities and the big boys etc not at some Chinese garage.
👍️0
Inthe203 Inthe203 8 년 전
I made over 680K on that stock. I've done well, thanks.

*Pats you on the head*

👍️0
Dutchdaan Dutchdaan 8 년 전
you just keep buying dolv.thinking it is the next tesla right? dream in son.
👍️0
Dutchdaan Dutchdaan 8 년 전
yes i do.
👍️0
Inthe203 Inthe203 8 년 전
You're going to put weight into the words of Martin Shkreli? LOL

If anyone reads that - they will side with me. Martin is a shyster!
👍️0
Dutchdaan Dutchdaan 8 년 전
Newb martin Shkreli and goldman both say it is a buy and you think it is a sell. it is undervalued look at the numbers. and not for 1 hour. study them 1 week. strong buy
👍️0
Inthe203 Inthe203 8 년 전
Stop pumping this stock.

The demise of this company was the purchase of Synageva and the bloated price they paid. They never recovered. Also the failed sales projections on their drugs.

They've been incorrect on all profit projections and their company value has been cut in half.

That being said, the stock price should be too. This stock price should be more in line with $60.00 per share.

Look at their layoffs. They are dumping people left and right. They received a huge tax break from the governor for staying in Connecticut if they create jobs, but that's not happening.

And you'll see more layoffs to come. I'd like to know how they're not reneging on the governor's agreement of creating more jobs.

You must own stock in this and now underwater.



👍️0

최근 히스토리

Delayed Upgrade Clock